Janciauskiene Sabina, Olejnicka Beata, Koczulla Rembert, Cardell Lars-Olaf, Welte Tobias, Westin Ulla
Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
Am J Rhinol Allergy. 2014 May-Jun;28(3):e136-40. doi: 10.2500/ajra.2014.28.4038.
It has been observed that patients with allergic asthma/rhinitis have increased apoptosis of peripheral blood cells. This study was designed to explore the idea that the markers of apoptosis may help predict the response of allergen immunotherapy.
The Allergy Department of University Hospital, Malmö, Sweden, recruited a total of 58 young adults (<35 years) with a history of birch pollen/grass pollen-induced allergic rhinitis. Their diagnoses were verified by positive skin-prick tests and the presence of serum-specific immunoglobulin E antibodies toward birch and/or grass pollen. Plasma samples were obtained from 34 patients before the start of immunotherapy and 24 patients after treatment. The control group consisted of 38 nonallergic individuals. The levels of plasma gelsolin, soluble forms of Fas (sFas) and Fas ligand (Fas-L), the chemokine CCL17 (thymus- and activation-regulated chemokine), and tissue inhibitor of metalloprotease (TIMP) 1, were measured by enzyme-linked immunosorbent assay.
In patients receiving immunotherapy plasma gelsolin levels were higher relative to those without immunotherapy (the median level was 23.97 μg/mL [range, 18-35.8 μg/mL] versus 21.2 μg/mL [range, 13.9-29.8 μg/mL]; p = 0.012) and were similar to those of healthy controls (24.7 μg/mL [range, 17.4-35.3 μg/mL]). Plasma levels of sFas, Fas-L, CCL17, and TIMP-1 did not differ between study groups. Only in controls did the plasma gelsolin levels inversely correlate to the levels of soluble Fas.
Allergen-specific immunotherapy increases plasma levels of gelsolin, an antioxidant and antiapoptotic protein.
据观察，过敏性哮喘/鼻炎患者外周血细胞凋亡增加。本研究旨在探讨凋亡标志物是否有助于预测变应原免疫治疗的反应。
瑞典马尔默大学医院过敏科共招募了58名有桦树花粉/草花粉诱发过敏性鼻炎病史的年轻成年人（<35岁）。通过阳性皮肤点刺试验以及针对桦树和/或草花粉的血清特异性免疫球蛋白E抗体的存在来确诊。在免疫治疗开始前从34例患者获取血浆样本，治疗后从24例患者获取血浆样本。对照组由38名非过敏个体组成。采用酶联免疫吸附测定法测量血浆凝溶胶蛋白、可溶性Fas（sFas）和Fas配体（Fas-L）、趋化因子CCL17（胸腺和活化调节趋化因子）以及金属蛋白酶组织抑制剂（TIMP）1的水平。
接受免疫治疗的患者血浆凝溶胶蛋白水平相对于未接受免疫治疗的患者更高（中位数水平为23.97μg/mL[范围，18 - 35.8μg/mL]，而未接受免疫治疗的患者为21.2μg/mL[范围，13.9 - 29.8μg/mL]；p = 0.012），且与健康对照组相似（24.7μg/mL[范围，17.4 - 35.3μg/mL]）。研究组之间sFas、Fas-L、CCL17和TIMP-1的血浆水平无差异。仅在对照组中，血浆凝溶胶蛋白水平与可溶性Fas水平呈负相关。
变应原特异性免疫治疗可提高血浆凝溶胶蛋白水平，凝溶胶蛋白是一种抗氧化和抗凋亡蛋白。
